Nexavar and Vulval cellulitis - a phase IV clinical study of FDA data

Summary:

Vulval cellulitis is reported only by a few people who take Nexavar.

The phase IV clinical study analyzes which people take Nexavar and have Vulval cellulitis. It is created by eHealthMe based on reports of 22,516 people who have side effects while taking Nexavar from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 29, 2022

22,516 people reported to have side effects when taking Nexavar.
Among them, 4 people (0.02%) have Vulval cellulitis.


What is Nexavar?

Nexavar has active ingredients of sorafenib tosylate. It is often used in hepatocellular carcinoma. eHealthMe is studying from 22,624 Nexavar users for its effectiveness, alternative drugs and more.

What is Vulval cellulitis?

Vulval cellulitis (inflammation of skin around vagina) is found to be associated with 112 drugs and 57 conditions by eHealthMe.

Number of Nexavar and Vulval cellulitis reports submitted per year:

Could Nexavar cause Vulval cellulitis?

Time on Nexavar when people have Vulval cellulitis *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 100 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Age of people who have Vulval cellulitis when taking Nexavar *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Nexavar *:

  1. Norvasc: 4 people, 100.00%
  2. Crestor: 4 people, 100.00%

Common side effects people have besides Vulval cellulitis *:

  1. Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 100.00%
  2. Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 4 people, 100.00%
  3. Hyperkeratosis (thickening of the outer layer of the skin): 4 people, 100.00%
  4. Fasciitis (infection of muscle surrounding tissue): 4 people, 100.00%
  5. White Blood Cell Count Increased: 1 person, 25.00%
  6. Neutrophil Count Increased (excess than normal number of neutrophil a type of blood cell): 1 person, 25.00%
  7. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 1 person, 25.00%

Common conditions people have *:

  1. Pain: 4 people, 100.00%
  2. Renal Cell Carcinoma Stage Iv (stage iv renal cell cancer have cancer that has spread to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Nexavar and have Vulval cellulitis?

Check whether Vulval cellulitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Vulval cellulitis and when was it recovered:

Expand to all the drugs that have ingredients of sorafenib tosylate:

Alternative drugs to, pros and cons of Nexavar:

Common Nexavar side effects:

Browse all side effects of Nexavar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Vulval cellulitis treatments and more:

COVID vaccines that are related to Vulval cellulitis:

All the drugs that are associated with Vulval cellulitis:

All the conditions that are associated with Vulval cellulitis:

How the study uses the data?

The study uses data from the FDA. It is based on sorafenib tosylate (the active ingredients of Nexavar) and Nexavar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: